Hennessy Advisors Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Hennessy Advisors Inc’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,100	Closed	-$2.96M	–	269
2022 Q4	$2.96M	Sell	4,100 -300	-7%	-$221K	0.19%	164
2022 Q3	$3.03M	Hold	4,400	–	–	0.21%	146
2022 Q2	$2.6M	Sell	4,400 -100	-2%	-$65K	0.16%	183
2022 Q1	$3.14M	Sell	4,500 -1,300	-22%	-$822K	0.16%	192
2021 Q4	$3.66M	Sell	5,800 -200	-3%	-$123K	0.21%	175
2021 Q3	$3.63M	Sell	6,000 -100	-2%	-$62.1K	0.22%	157
2021 Q2	$3.41M	Buy	6,100 +100	+2%	+$50.7K	0.19%	180
2021 Q1	$2.84M	Buy	+6,000	New	+$2.92M	0.17%	216
2018 Q1	–	Sell	-2,010	Closed	-$756K	–	410
2017 Q4	$756K	Buy	+2,010	New	+$814K	0.02%	298

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hennessy Advisors Inc's REGN Position: Q1 2023 in Review

Hennessy Advisors Inc sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 4,100 shares — an estimated $2.96M sold.

Hennessy Advisors Inc first reported a position in REGN in Q4 2017 and held it in 9 quarters. The position peaked at $3.66M in Q4 2021. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Hennessy Advisors Inc reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Hennessy Advisors Inc sold 4,100 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $2.96M.
Hennessy Advisors Inc first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Hennessy Advisors Inc's Regeneron Pharmaceuticals position peaked at $3.66M in Q4 2021.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Hennessy Advisors Inc's 13F filing for Q1 2023, filed 14 Apr 2023.